Profile - To The Moon

Shunnie

Posts · 0Posts · 0
Following · 0Following · 0
Followers · 0Followers · 0

- ShunnieShunnie
  ·2021-06-18
  Ooo
  Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress
  Shares of Clearside Biomedical(CLSD) jumped on Thursday after analysts at Wedbush tripled their pri
  Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress
  2.64K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-18
  Oh
  Sorry, this post has been deleted
  2.11K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-18
  Latest
  Sorry, this post has been deleted
  1.85K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-15
  Ok
  Sorry, this post has been deleted
  1.79K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-15
  Latest
  Sorry, this post has been deleted
  2.45K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-15
  Omai
  Sorry, this post has been deleted
  2.35K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-15
  Nice
  Sorry, this post has been deleted
  2.47K Comment
  Like
  Share
  Report
- ShunnieShunnie
  ·2021-06-15
  Nice
  Oil rises as threat of immediate Iran supply recedes
  TOKYO, June 15 (Reuters) - Oil prices rose on Tuesday, with Brent gaining for a fourth consecutive s
  Oil rises as threat of immediate Iran supply recedes
  2.14K Comment
  Like
  Share
  Report
No followers yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3568068031753789","uuid":"3568068031753789","gmtCreate":1604974935389,"gmtModify":1604974935389,"name":"Shunnie","pinyin":"shunnie","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.26%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":168891866,"gmtCreate":1623970108855,"gmtModify":1703824792734,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Ooo","listText":"Ooo","text":"Ooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168891866","repostId":"1179547045","repostType":4,"repost":{"id":"1179547045","kind":"news","pubTimestamp":1623941450,"share":"https://ttm.financial/m/news/1179547045?lang=en_US&edition=fundamental","pubTime":"2021-06-17 22:50","market":"us","language":"en","title":"Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1179547045","media":"thestreet","summary":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their pri","content":"<p>Shares of Clearside Biomedical(<b>CLSD</b>) &nbsp;jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.</p>\n<p>Wedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.</p>\n<p>\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.</p>\n<p>Shares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.</p>\n<p>Clearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.</p>\n<p>Earlier this week the company&nbsp;reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.</p>\n<p>Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.</p>\n<p>The company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.</p>\n<p>Earlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush ...</p>\n\n<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLSD":"Clearside Biomedical Inc."},"source_url":"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179547045","content_text":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.\n\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.\nShares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.\nClearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.\nEarlier this week the company reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.\nClearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.\nThe company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.\nEarlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.","news_type":1,"symbols_score_info":{"CLSD":0.9}},"isVote":1,"tweetType":1,"viewCount":2636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168893668,"gmtCreate":1623970060954,"gmtModify":1703824791086,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168893668","repostId":"2144874239","repostType":4,"isVote":1,"tweetType":1,"viewCount":2107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168178821,"gmtCreate":1623969122463,"gmtModify":1703824765337,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168178821","repostId":"2144156742","repostType":4,"isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187061057,"gmtCreate":1623730862379,"gmtModify":1704209822477,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187061057","repostId":"2143733619","repostType":4,"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187063526,"gmtCreate":1623730851965,"gmtModify":1704209821990,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187063526","repostId":"1138219989","repostType":4,"isVote":1,"tweetType":1,"viewCount":2448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187063991,"gmtCreate":1623730841113,"gmtModify":1704209820858,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Omai","listText":"Omai","text":"Omai","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187063991","repostId":"2143178756","repostType":4,"isVote":1,"tweetType":1,"viewCount":2351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187069339,"gmtCreate":1623730809421,"gmtModify":1704209819235,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187069339","repostId":"1127219232","repostType":4,"isVote":1,"tweetType":1,"viewCount":2468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187080415,"gmtCreate":1623730261737,"gmtModify":1704209808233,"author":{"id":"3568068031753789","authorId":"3568068031753789","name":"Shunnie","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3568068031753789","idStr":"3568068031753789"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187080415","repostId":"2143188731","repostType":4,"repost":{"id":"2143188731","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623723494,"share":"https://ttm.financial/m/news/2143188731?lang=en_US&edition=fundamental","pubTime":"2021-06-15 10:18","market":"fut","language":"en","title":"Oil rises as threat of immediate Iran supply recedes","url":"https://stock-news.laohu8.com/highlight/detail?id=2143188731","media":"Reuters","summary":"TOKYO, June 15 (Reuters) - Oil prices rose on Tuesday, with Brent gaining for a fourth consecutive s","content":"<p>TOKYO, June 15 (Reuters) - Oil prices rose on Tuesday, with Brent gaining for a fourth consecutive session, as the prospect of extra supply coming to the market soon from Iran faded with talks dragging on over the United States rejoining a nuclear agreement with Tehran.</p>\n<p>Brent crude was up by 43 cents, or 0.6%, at $73.29 a barrel by 0134 GMT, having risen 0.2% on Monday. U.S. oil gained 41 cents, or 0.6%, to $71.29 a barrel, having slipped 3 cents in the previous session.</p>\n<p>Indirect discussions between the United States and Iran, along with other parties to the 2015 deal on Tehran's nuclear programme, resumed on Saturday in Vienna and were described as \"intense\" by the European Union.</p>\n<p>A U.S. return to the deal would pave the way for the lifting of sanctions on Iran that would allow the OPEC member to resume exports of crude.</p>\n<p>It is \"looking increasingly unlikely that we will see the U.S. rejoin the Iranian nuclear deal before the Iranian Presidential Elections later this week,\" ING Economics said in a note.</p>\n<p>Other members of the Organization of Petroleum Exporting Countries (OPEC) along with major producers including Russia - a group known as OPEC+ - have been withholding output to support prices amid the pandemic.</p>\n<p>\"Additional supply from OPEC+ will be needed over the second half of this year, with demand expected to continue its recovery,\" ING said.</p>\n<p>To meet rising demand, U.S. drillers are also increasing output.</p>\n<p>U.S. crude production from seven major shale formations is forecast to rise by about 38,000 barrels per day (bpd) in July to around 7.8 million bpd, the highest since November, the U.S. Energy Information Administration said in its monthly outlook.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil rises as threat of immediate Iran supply recedes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil rises as threat of immediate Iran supply recedes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-15 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, June 15 (Reuters) - Oil prices rose on Tuesday, with Brent gaining for a fourth consecutive session, as the prospect of extra supply coming to the market soon from Iran faded with talks dragging on over the United States rejoining a nuclear agreement with Tehran.</p>\n<p>Brent crude was up by 43 cents, or 0.6%, at $73.29 a barrel by 0134 GMT, having risen 0.2% on Monday. U.S. oil gained 41 cents, or 0.6%, to $71.29 a barrel, having slipped 3 cents in the previous session.</p>\n<p>Indirect discussions between the United States and Iran, along with other parties to the 2015 deal on Tehran's nuclear programme, resumed on Saturday in Vienna and were described as \"intense\" by the European Union.</p>\n<p>A U.S. return to the deal would pave the way for the lifting of sanctions on Iran that would allow the OPEC member to resume exports of crude.</p>\n<p>It is \"looking increasingly unlikely that we will see the U.S. rejoin the Iranian nuclear deal before the Iranian Presidential Elections later this week,\" ING Economics said in a note.</p>\n<p>Other members of the Organization of Petroleum Exporting Countries (OPEC) along with major producers including Russia - a group known as OPEC+ - have been withholding output to support prices amid the pandemic.</p>\n<p>\"Additional supply from OPEC+ will be needed over the second half of this year, with demand expected to continue its recovery,\" ING said.</p>\n<p>To meet rising demand, U.S. drillers are also increasing output.</p>\n<p>U.S. crude production from seven major shale formations is forecast to rise by about 38,000 barrels per day (bpd) in July to around 7.8 million bpd, the highest since November, the U.S. Energy Information Administration said in its monthly outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DUG":"二倍做空石油与天然气ETF(ProShares)","SCO":"二倍做空彭博原油指数ETF","DWT":"三倍做空原油ETN","DDG":"ProShares做空石油与天然气ETF","USO":"美国原油ETF","UCO":"二倍做多彭博原油ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143188731","content_text":"TOKYO, June 15 (Reuters) - Oil prices rose on Tuesday, with Brent gaining for a fourth consecutive session, as the prospect of extra supply coming to the market soon from Iran faded with talks dragging on over the United States rejoining a nuclear agreement with Tehran.\nBrent crude was up by 43 cents, or 0.6%, at $73.29 a barrel by 0134 GMT, having risen 0.2% on Monday. U.S. oil gained 41 cents, or 0.6%, to $71.29 a barrel, having slipped 3 cents in the previous session.\nIndirect discussions between the United States and Iran, along with other parties to the 2015 deal on Tehran's nuclear programme, resumed on Saturday in Vienna and were described as \"intense\" by the European Union.\nA U.S. return to the deal would pave the way for the lifting of sanctions on Iran that would allow the OPEC member to resume exports of crude.\nIt is \"looking increasingly unlikely that we will see the U.S. rejoin the Iranian nuclear deal before the Iranian Presidential Elections later this week,\" ING Economics said in a note.\nOther members of the Organization of Petroleum Exporting Countries (OPEC) along with major producers including Russia - a group known as OPEC+ - have been withholding output to support prices amid the pandemic.\n\"Additional supply from OPEC+ will be needed over the second half of this year, with demand expected to continue its recovery,\" ING said.\nTo meet rising demand, U.S. drillers are also increasing output.\nU.S. crude production from seven major shale formations is forecast to rise by about 38,000 barrels per day (bpd) in July to around 7.8 million bpd, the highest since November, the U.S. Energy Information Administration said in its monthly outlook.","news_type":1,"symbols_score_info":{"SCO":0.9,"BZmain":0.9,"UCO":0.9,"DWT":0.9,"CLmain":0.9,"QMmain":0.9,"USO":0.9,"DDG":0.9,"DUG":0.9}},"isVote":1,"tweetType":1,"viewCount":2142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}